Video Experimental Relacionado
Updated: Feb 20, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
Progreso de la investigación sobre el papel de DDR1 en el cáncer y la estrategia de terapia dirigida
Xiaoying Guan1,2, Yajie Zhang3, Xiaoli Guan4
1Pathology Department, The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, Gansu, China.
Abstract:
Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by various types of collagen. Abnormal activation of DDR1 is closely related to the occurrence and development of solid tumors and plays an important role in the regulation of cell adhesion, survival, proliferation, migration, and invasion. Thus, DDR1 is a promising therapeutic target in the field of oncology. This review introduces the structural characteristics of DDR1, focusing on its role in tumor progression and related signaling pathways. It also explores the relationship between DDR1 and tumor chemotherapy resistance, and elaborates on the current research status and development prospects for inhibitors and antibodies targeting DDR1. Thus, the DDR1 inhibition strategy may serve as a new alternative for treating cancer patients.
Videos de Conceptos Relacionados
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Inhibition of Cdk Activity
M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Treatment Resistant Cancers
Abnormal Proliferation

